Tinengotinib

Phase 3Small molecule

TTransThera Sciences (Nanjing), Inc.

Tinengotinib is one of 74 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

CholangiocarcinomaActive, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

CholangiocarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Tinengotinib

TTransThera Sciences (Nanjing), Inc.

Phase 3

1 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Cholangiocarcinoma

NCT05948475

Q2 2027

PreclinicalRecruiting

Prostate Cancer

NCT06457919

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors

Available·TTransThera Sciences (Nanjing), Inc.··NCT06370013

Cholangiocarcinoma1 trial

A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma

Active, not recruiting·TTransThera Sciences (Nanjing), Inc.·Phase 3·NCT05948475·200 enrolled

Prostate Cancer1 trial

A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination With Androgen Receptor Signaling Inhibitors (ARSIs) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT06457919·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Tinengotinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tinengotinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tinengotinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TransThera Sciences (Nanjing), Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTransThera Sciences (Nanjing), Inc.

Tinengotinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Advanced Solid Tumors1 trial

Cholangiocarcinoma1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News